Prometic discontinues Phase II of PBI-4050 to treat cystic fibrosis related diabetes

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) said it will discontinue a Phase II trial of PBI-4050 to

Read the full 179 word article

User Sign In